BGLC
BioNexus Gene Lab Corp.
NASDAQ · Healthcare · Medical - Diagnostics & Research · MY
$1.23
+1.48%Year over year
Reported trailing growth
- Revenue
- -67.3%
- EBITDA
- +13.9%
- EBIT
- +13.2%
- EPS
- +22.7%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -12.1%
- EBITDA
- -96.9%
- EBIT
- —
- Net income
- -86.7%
- EPS
- -78.9%
- Free cash flow
- +23.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026